Inclusion Criteria:

          1. Pathological histology and/or cytology confirmed NSCLC;

          2. Based on AJCC Cancer Staging, IIIA, IIIB, IV lung cancer patients with NSCLC;

          3. PS 0-2;

          4. Expected survival > 3 months;

          5. Age 18~75 years old;

          6. The function of lung, liver, kidney, bone marrow was normal;

          7. The patients had not received radiotherapy for previous primary tumor and metastases;

          8. At least accept 2-4 cycles of chemotherapy,not disease progression after
             chemotherapy,start radiotherapy in two weeks after the last cycle of chemotherapy;

          9. Wild-type EGFR;

         10. Sensitive mutant EGFR, but refused to targeted therapy;

         11. In line with the indications of radiotherapy and accept it;

         12. Voluntarily enrolled to participate in,better compliance, cooperate with experimental
             observations, and sign informed consent.

        Exclusion Criteria:

          1. Vital organs (e.g., heart, liver, kidney) have serious dysfunction;

          2. Patients with other malignancies;

          3. Patients with a history of autoimmune disease;

          4. The patients are pregnant and lactating (Women of childbearing age need to check the
             pregnancy test);

          5. In the activity of acute or chronic infectious diseases;

          6. Patients with a clear history of drug allergy or allergic genus;

          7. Patients with participating in other clinical trials at the same time;

          8. Other cases that researchers believe that patients should not participate in the
             present trial.